Literature DB >> 264686

Glucose homeostasis during prolonged suppression of glucagon and insulin secretion by somatostatin.

R S Sherwin, R Hendler, R DeFronzo, J Wahren, P Felic.   

Abstract

Somatostatin was infused for 5-8 hr into five normal men and eleven normal, conscious dogs. This infusion resulted in a persistent decline in plasma glucagon (40-60%) and insulin (30-45%). Plasma gluccose fell 15-25% during the initial 1-2 hr, but subsequently rose to hyperglycemic levels (130-155 mg/100ml) by 3-6 hr, despite persistent hypoglucagonemia. Glucose production initially declined by 40-50%, but later rose to levels 15-20% above basal rates while peripheral glucose utilization fell to levels 20-30% below basal, thereby accounting for hyperglycemia. Infusion of exogenous insulin so as to restore plasma insulin to preinfusion values or cessation of the somatostatin infusion with restoration of endogenous insulin secretion resulted in a prompt reduction of plasma glucose to baseline values. Prevention of the initial somatostatin-induced hypoglycemic response by intravenous infusion of glucose failed to prevent the delayed hyperglycemia. We conclude that somatostatin caused only transient hypoglycemia in normal subjects and that hyperglycemia eventually developes as a consequence of insulin deficiency. These data indicate that basal glucagon secretion is not essential for the development of fasting hyperglycemia and support the conclusion that insulin deficiency rather than glucagon excess is the primary factor responsible for abnormal glucose homeostasis in the diabetic.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 264686      PMCID: PMC393257          DOI: 10.1073/pnas.74.1.348

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Measurement of size and turnover rate of body glucose pool by the isotope dilution method.

Authors:  R STEELE; J S WALL; R C DE BODO; N ALTSZULER
Journal:  Am J Physiol       Date:  1956-09

2.  Net splanchnic glucose production in normal man and in various disease states.

Authors:  J D MYERS
Journal:  J Clin Invest       Date:  1950-11       Impact factor: 14.808

3.  Glucagon control of fasting glucose in man.

Authors:  F P Alford; S R Bloom; J D Nabarro; R Hall; G M Besser; D H Coy; A J Kastin; A V Schally
Journal:  Lancet       Date:  1974-10-26       Impact factor: 79.321

4.  Inhibition of insulin secretion by somatostatin.

Authors:  K G Alberti; N J Christensen; S E Christensen; A P Hansen; J Iversen; K Lundbaek; K Seyer-Hansen; H Orskov
Journal:  Lancet       Date:  1973-12-08       Impact factor: 79.321

5.  Circulating C-peptide immunoreactivity. Studies in normals and diabetic patients.

Authors:  M B Block; M E Mako; D F Steiner; A H Rubenstein
Journal:  Diabetes       Date:  1972-10       Impact factor: 9.461

6.  Insulin control of glucose metabolism in man: a new kinetic analysis.

Authors:  P A Insel; J E Liljenquist; J D Tobin; R S Sherwin; P Watkins; R Andres; M Berman
Journal:  J Clin Invest       Date:  1975-05       Impact factor: 14.808

7.  Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man.

Authors:  J K Wise; R Hendler; P Felig
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

8.  Influence of endogenous insulin secretion on splanchnic glucose and amino acid metabolism in man.

Authors:  P Felig; J Wahren
Journal:  J Clin Invest       Date:  1971-08       Impact factor: 14.808

9.  Glucose dynamics in normal subjects and diabetic patients before and after a glucose load.

Authors:  N Forbath; G Hetenyi
Journal:  Diabetes       Date:  1966-11       Impact factor: 9.461

10.  Splanchnic and peripheral glucose and amino acid metabolism in diabetes mellitus.

Authors:  J Wahren; P Felig; E Cerasi; R Luft
Journal:  J Clin Invest       Date:  1972-07       Impact factor: 14.808

View more
  21 in total

Review 1.  Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.

Authors:  Philip E Cryer
Journal:  Endocrinology       Date:  2011-12-13       Impact factor: 4.736

2.  Glucagon physiology and aging: evidence for enhanced hepatic sensitivity.

Authors:  D C Simonson; R A DeFronzo
Journal:  Diabetologia       Date:  1983-07       Impact factor: 10.122

3.  Epinephrine-induced insulin resistance in man.

Authors:  D C Deibert; R A DeFronzo
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

4.  Rates of noninsulin-mediated glucose uptake are elevated in type II diabetic subjects.

Authors:  A D Baron; O G Kolterman; J Bell; L J Mandarino; J M Olefsky
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

5.  Glucagon sensitivity and clearance in type 1 diabetes: insights from in vivo and in silico experiments.

Authors:  Ling Hinshaw; Ashwini Mallad; Chiara Dalla Man; Rita Basu; Claudio Cobelli; Rickey E Carter; Yogish C Kudva; Ananda Basu
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-07-07       Impact factor: 4.310

6.  Influence of basal insulin and glucagon secretion on potassium and sodium metabolism. Studies with somatostatin in normal dogs and in normal and diabetic human beings.

Authors:  R A DeFronzo; R S Sherwin; M Dillingham; R Hendler; W V Tamborlane; P Felig
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

7.  Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes.

Authors:  R DeFronzo; D Deibert; R Hendler; P Felig; V Soman
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

8.  Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin.

Authors:  R A DeFronzo; J D Tobin; J W Rowe; R Andres
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

9.  Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding.

Authors:  R A DeFronzo; V Soman; R S Sherwin; R Hendler; P Felig
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

10.  Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus.

Authors:  O G Kolterman; R S Gray; J Griffin; P Burstein; J Insel; J A Scarlett; J M Olefsky
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.